Cargando…

Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment

A worldwide health concern, osteoporosis (OP), increases the risk of bone fracture and results in morbidity. This study examined whether the representative bone absorption marker serum tartrate-resistant acid phosphatase 5b (TRACP-5b) or bone formation marker bone alkaline phosphatase (BAP) could es...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, Yukio, Suzuki, Takako, Kato, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640396/ https://www.ncbi.nlm.nih.gov/pubmed/29062234 http://dx.doi.org/10.2147/TCRM.S142828

Ejemplares similares

Significant improvement of bone mineral density by denosumab treatment in Japanese osteoporotic patients following breast cancer treatment
por: Nakamura, Yukio, et al.
Publicado: (2018)

Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients
por: Suzuki, Takako, et al.
Publicado: (2017)

Vitamin D and Calcium Addition during Denosumab Therapy over a Period of Four Years Significantly Improves Lumbar Bone Mineral Density in Japanese Osteoporosis Patients
por: Suzuki, Takako, et al.
Publicado: (2018)

Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis
por: Suzuki, Takako, et al.
Publicado: (2018)

Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis
por: Suzuki, Takako, et al.
Publicado: (2018)

Denosumab significantly improves lumbar spine bone mineral density more in treatment-naïve than in long-term bisphosphonate-treated patients
por: Suzuki, Takako, et al.
Publicado: (2018)

Alkaline phosphatase is a predictor of Bone Mineral Density in postmenopausal females
por: Tariq, Sundus, et al.
Publicado: (2019)

Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women
por: Nakamura, Yukio, et al.
Publicado: (2017)

Pretreatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy
por: Kamimura, Mikio, et al.
Publicado: (2018)

Association of serum chemerin with calcium, alkaline phosphatase and bone mineral density in postmenopausal females
por: Tariq, Saba, et al.
Publicado: (2021)

Efficacy of Denosumab for Osteoporosis in Two Patients with Adult-Onset Still’s Disease—Denosumab Efficacy in Osteoporotic Still’s Disease Patients
por: Kumaki, Daiki, et al.
Publicado: (2018)

Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
por: Uehara, Masashi, et al.
Publicado: (2021)

Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2017)

OR13-06 Romosozumab After Denosumab Improves Lumbar Spine Bone Mineral Density And Microarchitecture Greater Than Denosumab Continuation In Postmenopausal Women
por: Hong, Namki, et al.
Publicado: (2023)

Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
por: Chen, Yi, et al.
Publicado: (2021)

Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
por: Sánchez, A., et al.
Publicado: (2016)

Bone Alkaline Phosphatase and Urine Hydroxyproline Assay in Pre and Postmenopausal Women in the State of Sikkim and its Correlation with Bone Mineral Density
por: Rai, Anne Deborah, et al.
Publicado: (2021)

Associations between bone-alkaline phosphatase and bone mineral density in adults with and without diabetes
por: Chen, Hailing, et al.
Publicado: (2018)

Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women
por: Augoulea, A., et al.
Publicado: (2017)

Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients
por: Kamimura, M., et al.
Publicado: (2016)

Comparison of Denosumab and Zoledronic Acid in Postmenopausal Women With Osteoporosis: Bone Mineral Density (BMD) and Trabecular Bone Score (TBS)
por: Kang, Taewook, et al.
Publicado: (2022)

The correlation between serum total alkaline phosphatase and bone mineral density in young adults
por: Shu, Juntao, et al.
Publicado: (2022)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

Bone Alkaline Phosphatase and Tartrate-Resistant Acid Phosphatase: Potential Co-regulators of Bone Mineralization
por: Halling Linder, Cecilia, et al.
Publicado: (2017)

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis
por: Dempster, David W, et al.
Publicado: (2018)

Discontinuation of Denosumab: Gradual Decrease in Doses Preserves Half of the Bone Mineral Density Gain at the Lumbar Spine
por: Laroche, Michel, et al.
Publicado: (2023)

Bone Mineral Density After Transitioning From Denosumab to Alendronate
por: Kendler, David, et al.
Publicado: (2019)

The Relationship Between Bone Mineral Density and Lumbar Disc Herniation in Postmenopausal Women
por: Çelen, Zekeriya Ersin, et al.
Publicado: (2023)

Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors
por: Asaoka, Daisuke, et al.
Publicado: (2016)

Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates
por: Kaneko, Tetsuya, et al.
Publicado: (2019)

Effects of Denosumab on Bone Metabolic Markers and Bone Mineral Density in Patients Treated with Glucocorticoids
por: Sawamura, Masato, et al.
Publicado: (2017)

Can lumbar spine bone mineral density predict readmission in denosumab-treated patients with chronic kidney disease?
por: Cheng, Ben-Chung, et al.
Publicado: (2017)

The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density
por: van der Burgh, Anna C., et al.
Publicado: (2021)

Baseline Characteristics and Changes in Bone Mineral Density T-Scores of Bulgarian Women with Postmenopausal Osteoporosis Receiving Denosumab in Routine Clinical Practice
por: Boyanov, Mihail, et al.
Publicado: (2016)

The comparable efficacy of denosumab on bone mineral density in rheumatoid arthritis patients with postmenopausal osteoporosis: A retrospective case-control study
por: Kim, Seong-Kyu, et al.
Publicado: (2023)

Analysis of three-dimensional bone mineral density and bone strength measured by quantitative computed tomography following denosumab discontinuation in a patient with postmenopausal osteoporosis
por: Tsuchiya, Koki, et al.
Publicado: (2019)

Efficacy, safety, and compliance of ibandronate treatment for 3 years in postmenopausal Japanese women with primary osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2018)

Longitudinal changes in bone mineral density, bone mineral content and bone area at the lumbar spine and hip in postmenopausal women, and the influence of abdominal aortic calcification
por: Bristow, Sarah M., et al.
Publicado: (2018)

Alkaline Phosphatase in Bone Tumours
por: Chitre, R. G.
Publicado: (1943)

Prediction of lumbar spine bone mineral density from the mandibular cortical width in postmenopausal women
por: Hekmatin, Ehsan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vbc72u3neko8pglcfj6p4guq9h